Vassiliki Karantza
0000-0003-4017-7858
Publication & Citation Trends
Publications
0 total
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study
Cited by 2
Semantic Scholar
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial OA
Cited by 123
Semantic Scholar
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
Cited by 7
Semantic Scholar
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study OA
Cited by 5
Semantic Scholar
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy OA
Cited by 4
Semantic Scholar
Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)
Cited by 0
Semantic Scholar
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC OA
Cited by 28
Semantic Scholar
A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers
Cited by 4
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(92)
Advanced Breast Cancer Therapies
(62)
Breast Cancer Treatment Studies
(40)
HER2/EGFR in Cancer Research
(32)
Autophagy in Disease and Therapy
(30)
Affiliations
Rutgers, The State University of New Jersey
Champalimaud Foundation
Ulsan College
Roche (Switzerland)
Cedars-Sinai Medical Center
External Profiles
Continue on JournalsHub
Put what you just read into practice with these free tools.